Jpmorgan Chase & CO Freeline Therapeutics Holdings PLC Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
SELL
$0.69 - $1.12 $458 - $743
-664 Closed
0 $0
Q1 2022

May 11, 2022
BUY
$0.92 - $2.03 $610 - $1,347
664 New
664 $1,000

Others Institutions Holding FRLN

# of Institutions
1
Shares Held
30.1K
Call Options Held
0
Put Options Held
0
View Full List

About Freeline Therapeutics Holdings plc

FRLN Quotes by TradingView
  • Ticker FRLN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,972,300
  • Description
  • Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...
More about FRLN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email